Cargando…
Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials
BACKGROUND: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival. METHODS: Data and samples fr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206103/ https://www.ncbi.nlm.nih.gov/pubmed/36966233 http://dx.doi.org/10.1038/s41416-023-02217-x |
_version_ | 1785046154122100736 |
---|---|
author | Athauda, Avani Nankivell, Matthew Langer, Rupert Pritchard, Susan Langley, Ruth E. von Loga, Katharina Starling, Naureen Chau, Ian Cunningham, David Grabsch, Heike I. |
author_facet | Athauda, Avani Nankivell, Matthew Langer, Rupert Pritchard, Susan Langley, Ruth E. von Loga, Katharina Starling, Naureen Chau, Ian Cunningham, David Grabsch, Heike I. |
author_sort | Athauda, Avani |
collection | PubMed |
description | BACKGROUND: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival. METHODS: Data and samples from two large prospective randomised trials (UK MRC OE05 and ST03) were pooled. Stained slides were available for central pathology review from 1619 patients. Mandard tumour regression grade (TRG) and regression of tumour within LNs (LNR: scored as present/absent) were assessed and correlated with overall survival (OS) using a Cox regression model. An exploratory analysis to define subgroups with distinct prognoses was conducted using a classification and regression tree (CART) analysis. RESULTS: Neither trial demonstrated a relationship between TRG score and the presence or absence of LNR. In univariable analysis, lower TRG, lower ypN stage, lower ypT stage, presence of LNR, presence of well/moderate tumour differentiation, and absence of tumour at resection margin were all associated with better OS. However, the multivariable analysis demonstrated that only ypN, ypT, grade of differentiation and resection margin (R0) were independent indicators of prognosis. Exploratory CART analysis identified six subgroups with 3-year OS ranging from 83% to 22%; with ypN stage being the most important single prognostic variable. CONCLUSIONS: Pathological LN stage within the resection specimen was the single most important determiner of survival. Our results suggest that the assessment of regression changes within the primary tumour or LNs may not be necessary to define the prognosis further. |
format | Online Article Text |
id | pubmed-10206103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102061032023-05-25 Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials Athauda, Avani Nankivell, Matthew Langer, Rupert Pritchard, Susan Langley, Ruth E. von Loga, Katharina Starling, Naureen Chau, Ian Cunningham, David Grabsch, Heike I. Br J Cancer Article BACKGROUND: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival. METHODS: Data and samples from two large prospective randomised trials (UK MRC OE05 and ST03) were pooled. Stained slides were available for central pathology review from 1619 patients. Mandard tumour regression grade (TRG) and regression of tumour within LNs (LNR: scored as present/absent) were assessed and correlated with overall survival (OS) using a Cox regression model. An exploratory analysis to define subgroups with distinct prognoses was conducted using a classification and regression tree (CART) analysis. RESULTS: Neither trial demonstrated a relationship between TRG score and the presence or absence of LNR. In univariable analysis, lower TRG, lower ypN stage, lower ypT stage, presence of LNR, presence of well/moderate tumour differentiation, and absence of tumour at resection margin were all associated with better OS. However, the multivariable analysis demonstrated that only ypN, ypT, grade of differentiation and resection margin (R0) were independent indicators of prognosis. Exploratory CART analysis identified six subgroups with 3-year OS ranging from 83% to 22%; with ypN stage being the most important single prognostic variable. CONCLUSIONS: Pathological LN stage within the resection specimen was the single most important determiner of survival. Our results suggest that the assessment of regression changes within the primary tumour or LNs may not be necessary to define the prognosis further. Nature Publishing Group UK 2023-03-25 2023-06-15 /pmc/articles/PMC10206103/ /pubmed/36966233 http://dx.doi.org/10.1038/s41416-023-02217-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Athauda, Avani Nankivell, Matthew Langer, Rupert Pritchard, Susan Langley, Ruth E. von Loga, Katharina Starling, Naureen Chau, Ian Cunningham, David Grabsch, Heike I. Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials |
title | Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials |
title_full | Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials |
title_fullStr | Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials |
title_full_unstemmed | Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials |
title_short | Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials |
title_sort | pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable og cancer: pooled analysis of two trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206103/ https://www.ncbi.nlm.nih.gov/pubmed/36966233 http://dx.doi.org/10.1038/s41416-023-02217-x |
work_keys_str_mv | AT athaudaavani pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials AT nankivellmatthew pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials AT langerrupert pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials AT pritchardsusan pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials AT langleyruthe pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials AT vonlogakatharina pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials AT starlingnaureen pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials AT chauian pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials AT cunninghamdavid pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials AT grabschheikei pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials |